Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2023-04-21 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
关于召开2022年度业绩说明会的公告
Investor Presentation Classification · 85% confidence The document is an announcement about the scheduling and details of a 2022 annual performance explanation meeting (业绩说明会) by 科兴生物制药股份有限公司. It mentions the date, time, location, and format of the meeting, as well as instructions for investor participation and questions. The document does not contain actual financial data or detailed financial analysis but serves to inform investors about the upcoming event where such information will be discussed. The document length is short (1514 characters), and it is clearly an announcement rather than the report or transcript itself. Therefore, it fits the category of an Investor Presentation announcement or meeting notice. Given the options, the best fit is Investor Presentation (IP), as it is a detailed presentation for investors focusing on financials, strategy, and market position, even though this is an announcement of the meeting rather than the presentation itself. However, since the document is primarily about the meeting announcement and not the presentation content, and given the short length, it aligns more closely with an Investor Presentation (IP) category rather than a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2023-04-21 Chinese
关于调整2022年限制性股票激励计划授予价格的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the adjustment of the grant price for a 2022 restricted stock incentive plan by the company 科兴生物制药股份有限公司. It details board and supervisory approvals, independent director opinions, legal and financial advisor opinions, and the rationale for the price adjustment. The document is a formal announcement of a corporate action related to stock incentives, specifically a change in the terms of an existing equity incentive plan. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a full annual or interim report, nor is it a proxy solicitation or voting result announcement. The content fits best under a regulatory announcement category related to corporate governance and equity incentive plan updates. Given the nature of the document as an official announcement of a corporate action (adjustment of stock incentive plan grant price), and considering the document length is under 5,000 characters and it is an announcement rather than a full report, the most appropriate classification is Regulatory Filings (RNS).
2023-04-21 Chinese
2022年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled "内部控制审计报告" which translates to "Internal Control Audit Report". It is issued by a certified public accounting firm and addresses the effectiveness of internal controls over financial reporting as of December 31, 2022. The content includes the auditor's responsibility, the company's responsibility, and an audit opinion on internal control effectiveness. This is a standalone audit report focused on internal control over financial reporting, not a full annual report or financial statement. It matches the description of an Audit Report / Information (AR) filing, which includes audit reports and applied accounting principles but excludes full annual reports. The document length is 5656 characters, sufficient to contain substantive audit content rather than a brief announcement or certification letter. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-21 Chinese
关于2022年度营业收入扣除事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查意见" (Special Audit Opinion) regarding the deduction of operating income for the fiscal year 2022 (January 1, 2022 to December 31, 2022). It is issued by a certified public accounting firm (Da Hua Certified Public Accountants) and references an audit report number (大华审字[2023]0010676号审计报告). The document contains detailed financial information specifically about operating income deductions and the auditor's special verification opinion on this matter. It is not a full annual report (10-K), nor a general audit report of the entire financial statements, but a standalone audit opinion on a specific financial matter related to revenue deductions. The document length (8065 characters) and content indicate it is a substantive audit opinion rather than a brief announcement or certification letter. Therefore, it fits the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial issues.
2023-04-21 Chinese
非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" (special audit report) concerning non-operating fund occupation and other related party fund transactions for the year 2022. It includes detailed tables of financial data related to these transactions. The presence of an audit firm (大华会计师事务所) and the nature of the content indicate this is a standalone audit report focusing on specific financial audit matters rather than a full annual report or interim report. The document length is relatively short (2124 characters), but it contains substantive financial data and audit findings, not merely an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR). FY 2022
2023-04-21 Chinese
独立董事关于公司对外担保情况的专项说明及独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees for the year 2022. It references regulatory requirements and provides an assessment of the company's compliance and risk control related to external guarantees. The document is short (611 characters) and focuses on a specific governance-related topic rather than a full financial report or audit. It does not contain comprehensive financial data or audit results but is a formal statement by directors on a particular issue. This fits best under Regulatory Filings (RNS) as it is a regulatory disclosure that does not fit other specific categories like Audit Report or Annual Report.
2023-04-21 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.